The EGF receptor interacts with the type 1 IGF receptor and regulates its stability

Biochemical and Biophysical Research Communications

Volumn 355, Issue 3, 2007, Pages 707-714

  Riedemann, Johann ^a   Takiguchi, Megumi ^a   Sohail, Muhammad ^b   Macaulay, Valentine M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

EGFR; IGF1R; Interaction; siRNA; Ubiquitylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; KNOCKOUT GENE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SQUAMOUS CELL CARCINOMA; UBIQUITINATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DIMERIZATION; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; UBIQUITIN;

EID: 33847321518     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.012     Document Type: Article

References (27)

1. Adams T.E., McKern N.M., and Ward C.W. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 22 (2004) 89-95
2. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 Suppl. 1 (2000) 25-32 discussion 41--22
3. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
4. Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E., et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5 (1986) 2503-2512
5. Slaaby R., Schaffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C., Mathiasen I.S., and Brandt J. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281 (2006) 25869-25874
6. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319 (2004) 1-11
7. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62 (2002) 200-207
8. Warshamana-Greene G.S., Litz J., Buchdunger E., Garcia-Echeverria C., Hofmann F., and Krystal G.W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res. 11 (2005) 1563-1571
9. Ward C.W., and Garrett T.P. Structural relationships between the insulin receptor and epidermal growth factor receptor families and other proteins. Curr. Opin. Drug Discov. Devel. 7 (2004) 630-638
10. Bohula E.A., Salisbury A.J., Sohail M., Playford M.P., Riedemann J., Southern E.M., and Macaulay V.M. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278 (2003) 15991-15997
11. Rochester M.A., Riedemann J., Hellawell G.O., Brewster S.F., and Macaulay V.M. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene. Ther. 12 (2005) 90-100
12. Vecchione A., Marchese A., Henry P., Rotin D., and Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol. Cell. Biol. 23 (2003) 3363-3372
13. Kruhoffer M., Jensen J.L., Laiho P., Dyrskjot L., Salovaara R., Arango D., Birkenkamp-Demtroder K., Sorensen F.B., Christensen L.L., Buhl L., Mecklin J.P., Jarvinen H., Thykjaer T., Wikman F.P., Bech-Knudsen F., Juhola M., Nupponen N.N., Laurberg S., Andersen C.L., Aaltonen L.A., and Orntoft T.F. Gene expression signatures for colorectal cancer microsatellite status and HNPCC. Br. J. Cancer 92 (2005) 2240-2248
14. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., and Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 (2002) RESEARCH0034
15. Grant S., Qiao L., and Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7 (2002) d376-d389
16. Balana M.E., Labriola L., Salatino M., Movsichoff F., Peters G., Charreau E.H., and Elizalde P.V. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20 (2001) 34-47
17. Nahta R., Yuan L.X., Zhang B., Kobayashi R., and Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65 (2005) 11118-11128
18. Ahmad T., Farnie G., Bundred N.J., and Anderson N.G. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J. Biol. Chem. 279 (2004) 1713-1719
19. Faraone D., Aguzzi M.S., Ragone G., Russo K., Capogrossi M.C., and Facchiano A. Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Blood 107 (2006) 1896-1902
20. Saito Y., Haendeler J., Hojo Y., Yamamoto K., and Berk B.C. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol. Cell. Biol. 21 (2001) 6387-6394
21. Lin X., Ruan X., Anderson M.G., McDowell J.A., Kroeger P.E., Fesik S.W., and Shen Y. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33 (2005) 4527-4535
22. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A., Lefkowitz R.J., and Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J. Biol. Chem. 280 (2005) 24412-24419
23. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274 (1999) 8865-8874
24. He W., Rose D.W., Olefsky J.M., and Gustafson T.A. Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J. Biol. Chem. 273 (1998) 6860-6867
25. Shih J.Y., Gow C.H., Yu C.J., Yang C.H., Chang Y.L., Tsai M.F., Hsu Y.C., Chen K.Y., Su W.P., and Yang P.C. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int. J. Cancer 118 (2006) 963-969
26. J. Riedemann, M. Sohail, V.M. Macaulay, Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells, Biochem. Biophys. Res. Commun. (2007), in press.
27. Morgillo, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66 (2006) 10100-10111